OncoMatch/Clinical Trials/NCT07464132

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

Is NCT07464132 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Injection of 68Ga-NI-FAPI for tumor.

Phase 1/2RecruitingPeking Union Medical College HospitalNCT07464132Data as of Jun 2026Location: China

Treatment: Injection of 68Ga-NI-FAPI — The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Injection of 68Ga-NI-FAPI

Demographics

Ages ≤ 85

Lab requirements

Kidney function

blood creatinine levels exceeding 159 μmol/L [excluded]

Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μmol/L)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07464132 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 85 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify